Affordable Access

deepdyve-link
Publisher Website

Inhibition of MEK confers hypersensitivity to X-radiation in the context of BRAF mutation in a model of childhood astrocytoma.

Authors
  • Studebaker, Adam1
  • Bondra, Kathryn2
  • Seum, Star2
  • Shen, Changxian1
  • Phelps, Doris A1
  • Chronowski, Christopher2
  • Leasure, Justin2
  • Smith, Paul D3
  • Kurmasheva, Raushan T1
  • Mo, Xiaokui4
  • Fouladi, Maryam5
  • Houghton, Peter J1
  • 1 Center for Childhood Cancer and Blood Diseases, Nationwide Children's Hospital, Columbus, Ohio.
  • 2 Wexner Medical Center at The Ohio State University, Arthur G. James Comprehensive Cancer Center and Richard L. Solove Research Institute, Columbus, Ohio.
  • 3 Astrazeneca Ltd., Oncology iMed, Macclesfield, UK.
  • 4 Center for Biostatistics, The Ohio State University, Columbus, Ohio.
  • 5 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Type
Published Article
Journal
Pediatric Blood & Cancer
Publisher
Wiley (John Wiley & Sons)
Publication Date
Oct 01, 2015
Volume
62
Issue
10
Pages
1768–1774
Identifiers
DOI: 10.1002/pbc.25579
PMID: 25981859
Source
Medline
Keywords
License
Unknown

Abstract

Selumetinib suppressed TORC1 signaling in the context of BRAF mutation. Selumetinib caused a rapid downregulation of FANCD2 and markedly potentiated the effect of XRT. These data suggest the possibility of potentiating the effect of XRT selectively in tumor cells by MEK inhibition in the context of mutant BRAF or maintaining tumor control at lower doses of XRT that would decrease long-term sequelae.

Report this publication

Statistics

Seen <100 times